MPV/S-2P
- Generic Name
- MPV/S-2P
NIH Launches Phase 1 Trial of Nasal COVID-19 Vaccine MPV/S-2P
• The NIH has initiated a Phase 1 clinical trial for MPV/S-2P, a novel nasal COVID-19 vaccine, across three U.S. sites, aiming for improved protection against emerging variants.
• MPV/S-2P utilizes a live-weakened murine pneumonia virus (MPV) to deliver a stabilized spike protein, potentially inducing a more robust mucosal immune response in the respiratory tract.
• The trial will involve 60 healthy adults who have already received at least three mRNA COVID-19 vaccine doses, evaluating the vaccine's safety and immune response at varying dosages.
• Researchers suggest nasal vaccines could offer advantages over traditional injections, including enhanced acceptance, easier storage, and potentially superior protection against the virus.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath